Skip to main content
NCBI home page
RSC Advances logoLink to RSC Advances
. 2024 Mar 4;14(11):7571. doi: 10.1039/d4ra90013h

Correction: Synthesis and anticancer evaluation of [d-Ala]-nocardiotide A

Rani Maharani a,b,c,✉, Muhamad Imam Muhajir a, Jelang Muhammad Dirgantara a,d, Ari Hardianto a, Tri Mayanti a,c, Desi Harneti a,c, Nurlelasari a,c, Kindi Farabi a,b,c, Ace Tatang Hidayat a,b,c, Unang Supratman a,b,c, Teruna Siahaan e,✉
PMCID: PMC10910442  PMID: 38440279

Abstract

Correction for ‘Synthesis and anticancer evaluation of [d-Ala]-nocardiotide A’ by Rani Maharani et al., RSC Adv., 2024, 14, 4097–4104, https://doi.org/10.1039/D4RA00025K.

The authors regret that there was an error in the presentation of the units in Fig. 5 in the original article. The correct version of Fig. 5 is presented below.

Fig. 5. The effect of the concentrations of nocardiotide A, [d-Ala]-nocardiotide A, and CFSRMC cyclic F5 on the morphology of cervical cancer HeLa cells. Both nocardiotide A and [d-Ala]-nocardiotide A completely disrupted the monolayer integrity of HeLa cells at a concentration of 62.50 μg mL−1, while CFSRMC cyclic F5 as a negative control did not disrupt the monolayer integrity of HeLa cells.

Fig. 5

Open in a new tab

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

Supplementary Material

Articles from RSC Advances are provided here courtesy of Royal Society of Chemistry

RESOURCES